Short Interest in China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Expands By 1,295.8%

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) was the target of a significant increase in short interest during the month of June. As of June 15th, there was short interest totaling 71,896 shares, an increase of 1,295.8% from the May 31st total of 5,151 shares. Currently, 0.2% of the shares of the company are sold short. Based on an average daily trading volume, of 220,625 shares, the short-interest ratio is currently 0.3 days.

Institutional Investors Weigh In On China SXT Pharmaceuticals

A number of hedge funds have recently modified their holdings of the business. XTX Topco Ltd acquired a new position in China SXT Pharmaceuticals in the 4th quarter valued at about $36,000. Virtu Financial LLC increased its position in shares of China SXT Pharmaceuticals by 107.5% during the 3rd quarter. Virtu Financial LLC now owns 28,983 shares of the company’s stock worth $46,000 after purchasing an additional 15,013 shares during the last quarter. Finally, Citadel Advisors LLC acquired a new stake in shares of China SXT Pharmaceuticals during the 3rd quarter worth about $78,000. 5.02% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised shares of China SXT Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Friday, June 5th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, China SXT Pharmaceuticals currently has a consensus rating of “Sell”.

China SXT Pharmaceuticals Stock Performance

NASDAQ SXTC opened at $2.35 on Friday. The stock’s 50 day simple moving average is $1.89 and its 200-day simple moving average is $41.98. China SXT Pharmaceuticals has a 1-year low of $1.25 and a 1-year high of $1,046.98.

China SXT Pharmaceuticals Company Profile

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.